A combination of OralinTM and oral agents significantly increased the insulin levels For years, diabetes researchers have searched for an alternative to injected insulin. A study presented at the ENDO 2002 press conference shows the efficacy of an oral insulin spray, called OralinTM, which is delivered inside of the mouth through the buccal mucosa, that has been developed by Generex Biotechnology Corporation. Researchers studied the effects of OralinTM on 13 subjects with type-2 diabetes in combination with oral agents as well as oral agents alone, and followed both by a 360-calorie meal.
“Our data shows that a combination of OralinTM and oral agents significantly increased the insulin levels,” said Dr. Jaime Guevara-Aguirre, an Ecuadorian researcher who worked with researchers from Generex on the study. “OralinTM also helped keep the glucose and c-peptide levels lower when compared with oral agents alone.”
Dr. Guevara-Aguirre noted the need for larger and longer studies to further test the effectiveness of oral insulin spray. Endo 2002